필라델피아 양성 급성골수성 백혈병에서 imatinib mesylate 투여로 완전관해 유도된 1예
Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
Abstract
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
참고문헌 (16)
- Soupir CP, "Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis", Am J Clin Pathol, 127, pp.642~650 (2007)
- Advani AS, "Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia", Leuk Res, 28, pp.545~546 (2004)
- Kantarjian H, "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", N Engl J Med, 346, pp.645~652 (2002)
- Druker BJ, "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", N Engl J Med, 344, pp.1038~1042 (2001)
- Berger R, "Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia", Leuk Lymphoma, 11(Suppl 1), pp.235~237 (1993)
- Altman AJ, "Clinical features and biological implications of acute mixed lineage (hybrid) leukemias", Am J Pediatr Hematol Oncol, 12, pp.123~133 (1990)
- Matutes E, "Definition of acute biphenotypic leukemia", Haematologica, 82, pp.64~66 (1997)
- Druker BJ, "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nat Med, 2, pp.561~566 (1996)
- Sawyers CL, "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study", Blood, 99, pp.3530~3539 (2002)
- Drummond MW, "Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome", Leukemia, 17, pp.463~465 (2003)
- 윤재호, "관해 유도 후 글리벡과 동종 조혈모세포 이식으로 치료한 필라델피아 염색체 양성 급성 골수성백혈병 3예", 대한내과학회지, 72(3), pp.326~330 (2007), 대한내과학회
- Topaly J, "Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells", Leukemia, 15, pp.342~347 (2001)
- Viniou NA, "Ida-FLAG plus Imatinib Mesylate-induced molecular remission in a patient with chemoresistant Ph1(+) acute myeloid leukemia", Eur J Haematol, 72, pp.58~60 (2004)
- Ito K, "Successful treatment with imatinib mesylate in a case of minor BCR-ABL positive acute myelogenous leukemia", Int J Hematol, 81, pp.242~245 (2005)
- Pompetti F, "Long-term remission in BCR", ABL-positive AML-M6 patient treated with imatinib mesylate, 2007, pp.31, 563~567
- Ottmann OG, "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias", Blood, 100, pp.1965~1971 (2002)